BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-56. [PMID: 22696079 DOI: 10.1161/CIRCULATIONAHA.112.105890] [Cited by in Crossref: 152] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]
Number Citing Articles
1 Sardanelli F, Alì M, Hunink MG, Houssami N, Sconfienza LM, Di Leo G. To share or not to share? Expected pros and cons of data sharing in radiological research. Eur Radiol 2018;28:2328-35. [PMID: 29349697 DOI: 10.1007/s00330-017-5165-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
2 Peacock AJ, Crawley S, Mclure L, Blyth KG, Vizza CD, Poscia R, Francone M, Iacucci I, Olschewski H, Kovacs G, vonk Noordegraaf A, Marcus JT, van de Veerdonk MC, Oosterveer FP. Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy: The EURO-MR Study. Circ: Cardiovascular Imaging 2014;7:107-14. [DOI: 10.1161/circimaging.113.000629] [Cited by in Crossref: 103] [Cited by in F6Publishing: 38] [Article Influence: 12.9] [Reference Citation Analysis]
3 Dewachter L, Naeije R. Beraprost sodium MR for the treatment of pulmonary arterial hypertension. Expert Opinion on Orphan Drugs 2014;2:1315-23. [DOI: 10.1517/21678707.2014.961422] [Reference Citation Analysis]
4 Kaymaz C, Akbal OY, Hakgor A, Tokgoz HC, Tanyeri S. Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension. Pulm Circ 2018;8:2045894018780522. [PMID: 29767575 DOI: 10.1177/2045894018780522] [Reference Citation Analysis]
5 Richter MJ, Schermuly R, Seeger W, Rao Y, Ghofrani HA, Gall H. Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy. Pulm Circ 2016;6:516-23. [PMID: 28090293 DOI: 10.1086/688671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chakinala MM, Barst R. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. Pulm Circ 2013;3:507-22. [PMID: 24618537 DOI: 10.1086/674456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
7 Vizza CD, Sastry BK, Safdar Z, Harnisch L, Gao X, Zhang M, Lamba M, Jing ZC. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. BMC Pulm Med 2017;17:44. [PMID: 28228114 DOI: 10.1186/s12890-017-0374-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
8 Nathan SD, King CS. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther 2014;8:875-85. [PMID: 25061279 DOI: 10.2147/DDDT.S64907] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
9 Rusiecki J, Rao Y, Cleveland J, Rhinehart Z, Champion HC, Mathier MA. Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening. Pulm Circ 2015;5:701-6. [PMID: 26697177 DOI: 10.1086/683829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Nathan SD. Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat? Thorax 2014;69:107-8. [DOI: 10.1136/thoraxjnl-2013-204964] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Wolfson J, Henn L. Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints. Emerg Themes Epidemiol 2014;11:14. [PMID: 25342953 DOI: 10.1186/1742-7622-11-14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Picken C, Fragkos KC, Eddama M, Coghlan G, Clapp LH. Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E481. [PMID: 30970653 DOI: 10.3390/jcm8040481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
13 Ventetuolo CE, Gabler NB, Fritz JS, Smith KA, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Are hemodynamics surrogate end points in pulmonary arterial hypertension? Circulation 2014;130:768-75. [PMID: 24951771 DOI: 10.1161/CIRCULATIONAHA.114.009690] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
14 Bujkiewicz S, Thompson JR, Spata E, Abrams KR. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints. Stat Methods Med Res 2017;26:2287-318. [PMID: 26271918 DOI: 10.1177/0962280215597260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
15 Malekmohammad M, Folkerts G, Kashani BS, Naghan PA, Dastenae ZH, Khoundabi B, Garssen J, Mortaz E, Adcock IM. Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy. BMC Pulm Med 2019;19:188. [PMID: 31664957 DOI: 10.1186/s12890-019-0954-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, Hemnes AR, Kawut SM, Kline JA, Kolb TM, Mathai SC, Mercier O, Michelakis ED, Naeije R, Tuder RM, Ventetuolo CE, Vieillard-Baron A, Voelkel NF, Vonk-Noordegraaf A, Hassoun PM; American Thoracic Society Assembly on Pulmonary Circulation. Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2018;198:e15-43. [PMID: 30109950 DOI: 10.1164/rccm.201806-1160ST] [Cited by in Crossref: 95] [Cited by in F6Publishing: 48] [Article Influence: 31.7] [Reference Citation Analysis]
17 Brittain EL. Shuttling toward Improved Clinic-based Assessment of Exercise Capacity in Pulmonary Arterial Hypertension. Ann Am Thorac Soc 2021;18:26-7. [PMID: 33385227 DOI: 10.1513/AnnalsATS.202008-973ED] [Reference Citation Analysis]
18 Krishnan U, Horn EM. A Contemporary Approach to Pulmonary Arterial Hypertension. Curr Atheroscler Rep 2016;18:58. [PMID: 27491673 DOI: 10.1007/s11883-016-0608-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Harms HJ, van de Veerdonk MC, Lammertsma AA, Vonk Noordegraaf A, Bogaard HJ. Pulmonary vascular remodeling and right heart failure in pulmonary hypertension: future role of positron emission tomography in decoding the enigma. Transl Respir Med 2013;1:16. [PMID: 27234397 DOI: 10.1186/2213-0802-1-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Schlueter M, Beaudet A, Davies E, Gurung B, Karabis A. Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. BMC Pulm Med 2020;20:202. [PMID: 32723397 DOI: 10.1186/s12890-020-01241-4] [Reference Citation Analysis]
21 Tonelli AR, Alkukhun L, Arelli V, Ramos J, Newman J, McCarthy K, Pichurko B, Minai OA, Dweik RA. Value of impedance cardiography during 6-minute walk test in pulmonary hypertension. Clin Transl Sci 2013;6:474-80. [PMID: 24330692 DOI: 10.1111/cts.12090] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
22 Bhattacharya PT, Troutman GS, Mao F, Fox AL, Tanna MS, Zamani P, Grandin EW, Menachem JN, Birati EY, Chirinos JA, Mazimba S, Smith KA, Kawut SM, Forfia PR, Vaidya A, Mazurek JA. Right ventricular outflow tract velocity time integral-to-pulmonary artery systolic pressure ratio: a non-invasive metric of pulmonary arterial compliance differs across the spectrum of pulmonary hypertension. Pulm Circ 2019;9:2045894019841978. [PMID: 30880577 DOI: 10.1177/2045894019841978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Rhee RL, Gabler NB, Praestgaard A, Merkel PA, Kawut SM. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol 2015;67:2457-65. [PMID: 26016953 DOI: 10.1002/art.39220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chen M, Lai Y, Chen R, Lu J, Zhang Y, Liu H, Wang D, Zhong Y, Zheng Z, Hong C. Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis. Pulm Pharmacol Ther 2021;72:102100. [PMID: 34856365 DOI: 10.1016/j.pupt.2021.102100] [Reference Citation Analysis]
25 Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2019;321:2101-12. [PMID: 31162568 DOI: 10.1001/jama.2019.6717] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
26 Joseph P, Oliveira RKF, Eslam RB, Agarwal M, Waxman AB, Systrom DM. Fick principle and exercise pulmonary hemodynamic determinants of the six-minute walk distance in pulmonary hypertension. Pulm Circ 2020;10:2045894020957576. [PMID: 32994925 DOI: 10.1177/2045894020957576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Stewart RAH, Szalewska D, Stebbins A, Al-Khalidi HR, Cleland JGH, Rynkiewicz A, Drazner MH, White HD, Mark DB, Roy A, Kosevic D, Rajda M, Jasinski M, Leng CY, Tungsubutra W, Desvigne-Nickens P, Velazquez EJ, Petrie MC. Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart 2018;5:e000752. [PMID: 29531766 DOI: 10.1136/openhrt-2017-000752] [Reference Citation Analysis]
28 Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, Dumitrescu D, Halank M, Held M, Gall H, Pittrow D, Hoeper MM, Frankenstein L. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol 2018;107:460-70. [PMID: 29368137 DOI: 10.1007/s00392-018-1207-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
29 Lian TY, Jiang X, Jing ZC. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther. 2017;11:1195-1207. [PMID: 28458514 DOI: 10.2147/dddt.s117277] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 4.4] [Reference Citation Analysis]
30 Sanna L, Todea A. Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials? Respir Med Res 2022;81:100893. [PMID: 35523041 DOI: 10.1016/j.resmer.2022.100893] [Reference Citation Analysis]
31 Sun LY, Zhao H, Kang Y, Shen XD, Cai ZY, Shen JY, He B, Yang CD. Two-dimensional echocardiography in the assessment of long-term prognosis in patients with pulmonary arterial hypertension. PLoS One 2014;9:e114443. [PMID: 25485890 DOI: 10.1371/journal.pone.0114443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2015;192:1111-7. [PMID: 26291092 DOI: 10.1164/rccm.201507-1456OC] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
33 Ishak Gabra NB, Mahmoud O, Ishikawa O, Shah V, Altshul E, Oron M, Mina B. Pulmonary Arterial Hypertension and Therapeutic Interventions. Int J Angiol 2019;28:80-92. [PMID: 31384105 DOI: 10.1055/s-0039-1692452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
34 Demir R, Küçükoğlu MS. Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol 2015;15:249-54. [PMID: 25880178 DOI: 10.5152/akd.2015.5834] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
35 Kawut SM, Archer-Chicko CL, DeMichele A, Fritz JS, Klinger JR, Ky B, Palevsky HI, Palmisciano AJ, Patel M, Pinder D, Propert KJ, Smith KA, Stanczyk F, Tracy R, Vaidya A, Whittenhall ME, Ventetuolo CE. Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med 2017;195:360-8. [PMID: 27602993 DOI: 10.1164/rccm.201605-1024OC] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
36 Farber HW. Validation of the 6-Minute Walk in Patients With Pulmonary Arterial Hypertension: Trying to Fit a Square Peg Into a Round Hole? Circulation 2012;126:258-60. [DOI: 10.1161/circulationaha.112.118547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
37 Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, Fukuda K. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. BMC Pulm Med 2015;15:62. [PMID: 25971443 DOI: 10.1186/s12890-015-0037-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Sun Z, Zhao W, Yang K, Li X, Yu P. Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2021;100:e27324. [PMID: 34559151 DOI: 10.1097/MD.0000000000027324] [Reference Citation Analysis]
39 Shah T, Chin KM. Lessons from the COMPASS-3 Study. Pulm Circ 2018;8:2045893218757100. [PMID: 29384427 DOI: 10.1177/2045893218757100] [Reference Citation Analysis]
40 Matura LA, Shou H, Fritz JS, Smith KA, Vaidya A, Pinder D, Archer-Chicko C, Dubow D, Palevsky HI, Sommers MS, Kawut SM. Physical Activity and Symptoms in Pulmonary Arterial Hypertension. Chest 2016;150:46-56. [PMID: 26892602 DOI: 10.1016/j.chest.2016.02.633] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
41 Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, Velazquez EJ, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. Am Heart J 2015;170:419-29.e3. [PMID: 26385024 DOI: 10.1016/j.ahj.2015.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
42 Zhang X, Xu D. Effects of exercise rehabilitation training on patients with pulmonary hypertension. Pulm Circ 2020;10:2045894020937129. [PMID: 32685130 DOI: 10.1177/2045894020937129] [Reference Citation Analysis]
43 Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest 2015;147:188-97. [PMID: 25122150 DOI: 10.1378/chest.14-0263] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
44 Chazova IE, Martynyuk TV, Valieva ZS, Azizov VA, Barbarash OL, Veselova TN, Galyavich AS, Gorbachevsky SV, Zelveian PA, Lazareva IV, Mukarov MA, Nakonetchnikov SN, Saidova MA, Sarybaev AS, Stukalova OV, Shalaev SV, Shmalts AA. EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Evrazijskij kardiologičeskij žurnal 2020. [DOI: 10.38109/2225-1685-2020-1-78-122] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 9.5] [Reference Citation Analysis]
45 Yang J, Nies MK, Fu Z, Damico R, Korley FK, Hassoun PM, Ivy DD, Austin ED, Everett AD. Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2016;194:1264-72. [PMID: 27254543 DOI: 10.1164/rccm.201512-2498OC] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
46 Andrew Moore R. Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage. Arthritis Res Ther 2013;15 Suppl 3:S4. [PMID: 24267380 DOI: 10.1186/ar4176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
47 Smart NA, King N, Lambert JD, Pearson MJ, Campbell JL, Risom SS, Taylor RS. Exercise-based cardiac rehabilitation improves exercise capacity and health-related quality of life in people with atrial fibrillation: a systematic review and meta-analysis of randomised and non-randomised trials. Open Heart 2018;5:e000880. [PMID: 30613410 DOI: 10.1136/openhrt-2018-000880] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
48 Sun H, Stockbridge N, Ariagno RL, Murphy D, Nelson RM, Rodriguez W. Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension. J Perinatol 2016;36:1029-33. [PMID: 27416322 DOI: 10.1038/jp.2016.103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
49 Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung 2020;198:65-86. [PMID: 31722043 DOI: 10.1007/s00408-019-00289-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Mathai SC, Suber T, Khair RM, Kolb TM, Damico RL, Hassoun PM. Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. Ann Am Thorac Soc 2016;13:31-9. [PMID: 26492065 DOI: 10.1513/AnnalsATS.201412-572OC] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
51 Preston IR, Feldman J, White J, Franco V, Ishizawar D, Burger C, Waxman AB, Hill NS. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. Pulm Circ 2014;4:456-61. [PMID: 25621159 DOI: 10.1086/677360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
52 Zhang Y, Yu X, Jin Q, Luo Q, Zhao Z, Zhao Q, Yan L, Liu Z. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension. Heart Fail Rev. 2019;24:949-965. [PMID: 31044326 DOI: 10.1007/s10741-019-09798-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
53 Pandey A, Garg S, Khunger M, Garg S, Kumbhani DJ, Chin KM, Berry JD. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. Circ Heart Fail 2015;8:1032-43. [PMID: 26185169 DOI: 10.1161/CIRCHEARTFAILURE.115.002130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 8.4] [Reference Citation Analysis]
54 Billings CG, Lewis R, Hurdman JA, Condliffe R, Elliot CA, Thompson AAR, Smith IA, Austin M, Armstrong IJ, Hamilton N, Charalampopoulos A, Sabroe I, Swift AJ, Rothman AM, Wild JM, Lawrie A, Waterhouse JC, Kiely DG. The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. Pulm Circ 2019;9:2045894019848649. [PMID: 30997865 DOI: 10.1177/2045894019848649] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Fernandes CJ, Martins BC, Jardim CV, Ciconelli RM, Morinaga LK, Breda AP, Hoette S, Souza R. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcomes 2014;12:130. [PMID: 25176512 DOI: 10.1186/s12955-014-0130-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
56 Rosenkranz S, Ghofrani HA, Beghetti M, Ivy D, Frey R, Fritsch A, Weimann G, Saleh S, Apitz C. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101:1792-1799. [PMID: 26135803 DOI: 10.1136/heartjnl-2015-307832] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
57 Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ 2017;7:312-25. [PMID: 28597774 DOI: 10.1177/2045893217710639] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
58 Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, Meier C, Ghofrani AH, Minai O, Rinaldi P, Michelakis E, Oudiz RJ. Updating clinical endpoint definitions. Pulm Circ 2013;3:206-16. [PMID: 23662199 DOI: 10.4103/2045-8932.109920] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
59 White RJ, Parikh K, Allen R, Feldman J, Jerjez-Sanchez C, Pan L, Keogh AM, Vizza CD, Shapiro SM, Gordon K, Broderick M, Bartolome S. EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. Pulm Circ 2019;:2045894019866335. [PMID: 31290359 DOI: 10.1177/2045894019866335] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Chen YJ, Tu HP, Lee CL, Huang WC, Yang JS, Li CF, Chen CH, Lin KL. Comprehensive Exercise Capacity and Quality of Life Assessments Predict Mortality in Patients with Pulmonary Arterial Hypertension. Acta Cardiol Sin 2019;35:55-64. [PMID: 30713400 DOI: 10.6515/ACS.201901_35(1).20180608A] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
61 Zheng Y, Yang T, Chen G, Hu E, Gu Q, Xiong C. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol 2014;70:13-21. [PMID: 24026627 DOI: 10.1007/s00228-013-1583-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
62 Salvi D, Poffley E, Tarassenko L, Orchard E. App-Based Versus Standard Six-Minute Walk Test in Pulmonary Hypertension: Mixed Methods Study. JMIR Mhealth Uhealth 2021;9:e22748. [PMID: 34096876 DOI: 10.2196/22748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wang C, Jing ZC, Huang YG, Zhou DX, Liu ZH, Meier C, Nikkho S, Curram J, Zhang P, He JG. Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. Heart Asia 2016;8:74-82. [PMID: 27326239 DOI: 10.1136/heartasia-2015-010712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Maeda H, Takeda K, Urushihara H, Kurokawa T. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Cancer Rep (Hoboken) 2021;4:e1334. [PMID: 33455091 DOI: 10.1002/cnr2.1334] [Reference Citation Analysis]
65 Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J 2019;53:1801908. [PMID: 30545975 DOI: 10.1183/13993003.01908-2018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 25.0] [Reference Citation Analysis]
66 Nathan SD, Brown AW, Weir NA. Response. Chest 2014;145:1440-1. [PMID: 24889459 DOI: 10.1378/chest.14-0720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res 2014;115:115-30. [PMID: 24951762 DOI: 10.1161/CIRCRESAHA.115.301146] [Cited by in Crossref: 201] [Cited by in F6Publishing: 110] [Article Influence: 25.1] [Reference Citation Analysis]
68 Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One 2018;13:e0193226. [PMID: 29590122 DOI: 10.1371/journal.pone.0193226] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
69 Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013;143:315-23. [PMID: 22814814 DOI: 10.1378/chest.12-0270] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]